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Introduction
Immunotherapies with monoclonal antibodies targeting programed death 1 (PD-1) or programed death ligand 1 (PD-L1) have led to significant improvement of the treatment of patients with advanced disease in many cancer subtypes, including non-smallcell lung cancer (NSCLC). However, only a subset of patients, approximately 20% in NSCLC, benefit from these treatments in monotherapy according to the main phase III clinical trials in previously treated advanced NSCLC. The expression of PD-L1 protein by immunohistochemistry (IHC) in formalin fixed paraffin embedded (FFPE) samples from NSCLC patients was assessed in clinical trials using a proprietary standardized assay that was different for each drug. Most clinical trials have found some predictive value of PD-L1 expression on benefit to immunotherapy in pretreated patients with NSCLC, even if some benefit was observed in patients with negative results based on various thresholds [1] [2] [3] [4] . Moreover, even when no benefit was observed in the PD-L1 negative group of patients on immunotherapy when compared with chemotherapy, durable responses were observed in some patients, and toxicities were significantly lower in patients treated with these agents. Thus, the Food and Drug Administration (FDA) approved PD-L1 IHC assays as a complementary diagnostic test for nivolumab and atezolizumab in patients with previously treated NSCLC. In this setting, 22C3 PD-L1 assay was approved as a companion test for pembrolizumab as second line therapy with a positivity threshold of 1% of positive tumor cells since patients with tumors with <1% of tumor stained cells were not studied in the phase III registration trial [5] . More recently, the benefit of first-line pembrolizumab in preselected patients with PD-L1 positive (50% of tumor cells with the 22C3 assay) advanced NSCLC demonstrated in the Keynote-024 study [6] led to the approval of pembrolizumab for first line treatment in patients with PD-L1 positive NSCLC, meaning that PD-L1 testing will be required in the first line setting [7] .
To date, four standardized PD-L1 IHC assays are available: 22C3 and 28-8 pharmDx assays on Dako platforms [8, 9] , and SP142 and SP263 on Ventana platforms; each assay was developed in combination with a particular anti-PD-1 or anti-PD-L1 drug for testing of patients in clinical trials (pembrolizumab, nivolumab, atezolizumab and durvalumab, respectively). These assays differ in terms of characteristics of the primary monoclonal antibodies, the IHC platform type, the detection system used, the interpretation of staining and the relevant positivity thresholds identified in clinical trials [10] . Several recent studies have shown a close analytical performance of the 22C3, 28-8 and SP263 assays with respect to tumor cells staining in NSCLC [11] [12] [13] [14] , whereas the SP142 assay stained a lower percentage of tumor cells. These results may lead to the use of 22C3, 28-8 and SP263 as interchangeable tests for the assessment of tumor cell PD-L1 expression. Accordingly, the SP263 assay has been approved by the FDA as a complementary diagnostic test for nivolumab and a companion diagnostic test for pembrolizumab in NSCLC.
However, additional harmonization data for PD-L1 testing are required for several reasons. First, Dako and Ventana platforms are not universally available and testing may have to be performed locally, in particular in the first-line setting. Second, the standardized PD-L1 assays remain expensive and PD-L1 testing reimbursement is insufficient to date in several countries, including France. Finally, multiple tests with different assays will not be feasible on the same specimen considering the limited amount of tissue in most advanced stage NSCLC samples.
In this multicenter study, we aimed to compare the analytical performance of the 28-8, 22C3 and SP263 assays and laboratorydeveloped tests (LDTs) using the five most commonly used monoclonal antibodies (22C3, 28-8, E1L3N, SP142 and SP263) for PD-L1 staining in tumor cells and immune cells in NSCLC.
Methods Cases
Seven centers participated in the study. Each center provided FFPE tumor blocks from six resected NSCLC: three adenocarcinomas and three squamous cell carcinomas. For each tumor type, the three cases selected included one case with <1% of tumor cells stained for PD-L1 with local protocol, one case with 1%-49% and one case with at least 50%. Tumor blocks were centralized at the Centre Leon Berard (Lyon, France) and consecutive sections were cut. For each case, eight unstained slides were sent to each center. Among the 42 cases selected, one case was excluded from the study because of significant heterogeneity in PD-L1 staining between the first and the last sections.
PD-L1 immunohistochemistry
Among the seven participating centers, three performed stainings with the Dako AS Link 48 IHC platform, two with the Ventana Benchmark Ultra and two with the Leica Bond III. Each center performed IHC for PD-L1 across 41 cases using the following monoclonal antibodies: 22C3 (Dako, Glostrup, Denmark), 28-8 (Dako for the PD-L1 pharmDx assays on Dako platforms or Abcam, Cambridge, UK for LDT), E1L3N (Cell Signaling Technology, Danvers, MA), SP142 (Spring Bioscience, Pleasanton, CA) and SP263 (Ventana, Tucson, AZ). Staining with clone 22C3 and clone 28-8 on Dako platforms was performed with the corresponding Dako pharmDx assay. Staining with clone SP263 on the Ventana Benchmark Ultra platform was performed with the SP263 Ventana assay, whereas SP142 was used only as an LDT. For all other combinations of antibodies and IHC platforms, LDTs were established using the concentrated antibodies (supplementary Table S1 , available at Annals of Oncology online), excepted for clone SP263 that was only available as a prediluted antibody. In a preliminary step, sections from normal tonsil tissue from a single FFPE block and reference pictures from two cases with intermediate positivity on tumor cells stained with 22C3 and 28-8 Dako pharmDx assays were sent to the centers for harmonization of the LDTs. PD-L1 stainings were then performed on the whole series of cases within 3 months after cutting the sections. For each case, PD-L1 stainings were performed on total of 35 consecutive sections.
Pathological assessment of PD-L1 staining
Assessment of PD-L1 staining was performed by pathologists previously trained on the 28-8 and/or 22C3 Dako pharmDx assays. PD-L1 staining was scored in tumor cells and immune cells. The percentage of tumor cells with linear membranous staining at any intensity was reported following 28-8 and 22C3 Dako pharmDx assays interpretation guides. For immune cell staining, the percentage of tumor area covered by PD-L1 positive immune cells was reported. Before pathological assessment, all slides were deidentified in respect to centers antibodies and IHC platforms. To reduce inter and intraobserver variability in evaluating the stainings, all 35 stained sections for each case were scored consecutively by a single pathologist on the same day.
Statistical analyses
Concordance between assays was evaluated using weighted kappa coefficients and overall percentage of agreement related to specific thresholds. For tumor cells staining, concordance was evaluated using a weighted kappa with three categories: <1%, 1%-49% and 50% of tumor cells with membranous staining at any intensity. Overall percentages of agreement were determined according to 1% and 50% thresholds. For immune cells staining, concordance was evaluated using a weighted kappa with four categories: <1%, 1%-4%, 5%-9% and 10%. To evaluate the distribution of each monoclonal antibody and center, we performed polynomial trend curves. Correlations between distributions and their predictive curves were evaluated by squared correlation R 2 .
Results

Tumor cell staining
Staining of tumor cells with the standardized 22C3 Dako pharmDx, 28-8 Dako pharmDx and SP263 Ventana assays was compared. For each assay individually, we found a very high concordance (weighted kappa coefficient: 0.79-0.94) between centers ( Figure 1 ). To compare results across these three assays and to compare with LDT, we selected for each assay the results from a single center, based on the highest mean percentage of stained tumor cells. When comparing these three assays, we found a high correlation (weighted kappa coefficient: 0.71-0.89, Figures 1  and 2 ). The results from the 27 LDT performed in the study were each compared with one of the standardized PD-L1 assays. LDTs with clones 22C3, 28-8 and SP263 were compared with the selected standardized assay with the corresponding antibody on dedicated platform. The other LDTs performed with clone E1L3N and SP142 were compared with the SP263 assay, which had the highest mean value for the percentage of staining in tumor cells. To evaluate the analytical performance of LDTs, we considered that they should achieve at least a similar concordance with one of these three assays when compared with these three assays together. Based on this rule, we defined a weighted kappa concordance coefficient of at least 0.75 as a sufficient concordance for selection and further validation of the test. We found that 14/ 27 (51.8%) of PD-L1 LDT were concordant with one of the reference assays (Figure 2 and supplementary Figures S1 and S2, available at Annals of Oncology online). The overall percentage of agreement for the 1% and the 50% positivity thresholds was very similar to these results ( Table 1) . The results for the 5%, 10% and 80% thresholds are mentioned in supplementary Table S2 , available at Annals of Oncology online. In our experience, low concordance was mainly related to insufficient sensitivity in PD-L1 expression detection by some LDT.
Immune cell staining
Staining of immune cells was scored by pathologists trained on the 22C3 and/or 28-8 assays but not SP142 assay, which includes the evaluation of immune cells. The overall percentage of agreement for the 1%, 5% and 10% positivity thresholds was poor when comparing 28-8, 22C3 and SP263 assays as well as when comparing LDT to these assays (supplementary Table S3 , available at Annals of Oncology online).
Discussion
PD-L1 expression by IHC has been assessed in all clinical trials evaluating efficacy of anti-PD-1 and anti-PD-L1 agents. Our study and others [11] [12] [13] [14] have shown that the Dako 28-8 pharmDx, Dako 22C3 pharmDx and Ventana SP263 assays have a very close analytical performance for the staining of tumor cells in NSCLC samples. This finding is very important since it indicates that these three tests may be interchangeable for PD-L1 testing on tumor cells and that a single PD-L1 test could be performed for the three drugs associated with these assays in clinical trials (nivolumab, pembrolizumab and durvalumab, respectively). In particular, given the high proportion of pathology laboratories using Ventana platform across many countries, the SP263 assay may be used as a complementary diagnostic test for nivolumab and companion diagnostic test for pembrolizumab as approved by the FDA. We did not study the Ventana SP142 assay, but several of these studies [11, 14] have shown that it stained a significantly lower proportion of tumor cells.
The introduction of ready-to-use, highly standardized, assays has been in past years an improvement in the quality of predictive IHC, for instance for HER2 testing. Even if these assays were used in clinical trials, several issues may prevent pathologists from using them and lead to development of LDT instead. In particular, these assays are much more expensive, reimbursement for PD-L1 testing is insufficient in many countries and the adequate 
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type of IHC platform (Dako or Ventana for PD-L1) may not be available in some pathology laboratories. Thus, in an effort to evaluate the potential use of LDT, our study simultaneously evaluated the largest number of PD-L1 LDT to date using the most commonly used PD-L1 antibodies and IHC platforms available. Given that the Dako 28-8, Dako 22C3 and Ventana SP263 assays are considered to have sufficient analytical concordance, we defined that LDT should be able to achieve a similar concordance (e.g. based on the same statistical criteria) with one of these three assays for tumor cell staining. Since PD-L1 is expressed as a continuum of percentage and intensities, we have chosen to study the concordance based on the most clinically relevant thresholds to date, 1% and 50%, which are used in the companion diagnostic tests for pembrolizumab in pretreated and nonpretreated NSCLC, respectively. In order to simultaneously evaluate the concordance with respect to these two thresholds, we decided to use a weighted kappa and have found that the 0.75 threshold was very concordant with the 90% overall percentage of agreement. It should be kept in mind that every concordance rate depends on the distribution of values in the series of cases studied. We selected our series of cases to represent quite equally the three main categories of PD-L1 expression in NSCLC (e.g. <1%, 1%-49% and 50%) but, in real clinical practice, the prevalence for each category may not be similar, in particular when studying biopsies, where the negative cases (<1%) may be more frequent because of tumor sampling [15] . We found that approximately half of these LDT did not sufficiently correlate with the reference assays, mostly due to insufficient sensitivity. These nonconcordant tests did not achieve the adequate dynamic range, in particular since tumor cells with low PD-L1 expression were not detected, lowering the percentage of positive tumor cells in some cases. In our experience, tonsil tissue may not be the best control since intense epithelial cells staining in the crypts was observed with almost all protocols, whereas tumor cells staining differed significantly. Thus, selection of FFPE samples is critical to adequately validate the dynamic range of PD-L1 tests. The use of cell lines with various PD-L1 expression levels may be of interest since highly calibrated and standardized PD-L1 expression level can be achieved for large scale calibration.
Importantly, we found that all the PD-L1 antibodies have the ability to be used as LDT with concordant results with one of the three assays. This is concordant with the study by Gaule et al. [16] , showing by quantitative fluorescence that main PD-L1 antibodies can have a similar ability to detect PD-L1 and that conditions of IHC (including epitope retrieval, primary antibody conditions and amplification steps) explain to a large extent the discrepancies between PD-L1 tests. However, we observed that the clone SP263, used as a prediluted antibody, has a particular ability to give concordant results across all centers and platforms. It suggests that this antibody may be particularly easy to use for PD-L1 LDT harmonization across different technical IHC conditions. For other PD-L1 antibodies, the fact we did not find concordant protocols for some combinations of antibodies and platforms does not mean that harmonization could not be achieved, but that it may be more difficult to perform. For clinical practice, the choice of the antibody may be driven by the availability of adequate PD-L1 staining protocols for a particular IHC platform, the cost of the antibody but also in Europe the availability of CE-IVD labeling for the antibody, clones 28-8 (Abcam), E1L3N (Cell signaling) and SP142 (Spring Bioscience) used in this study being labeled for research use only (RUO). Our study has also shown that RUO antibodies, in particular the commonly used clone E1L3N, are able to achieve high concordance with Dako 28-8, Dako 22C3 or Ventana SP263 PD-L1 assays. Moreover, other antibodies recently commercialized may be used and their analytical performance for PD-L1 testing has to be further evaluated using various IHC platforms.
Immune cell PD-L1 expression in NSCLC has been included in the diagnostic scoring algorithm of only the SP142 assay to date. Thus, the clinical utility of immune cell PD-L1 expression is restricted to the treatment by atezolizumab. However, there is some biological rational and data for evaluating immune cell PD-L1 expression as part of PD-L1 testing in other tumor types, including urothelial carcinoma and head and neck squamous cell carcinoma, maybe requiring harmonization of immune cell PD-L1 testing in the future. Moreover, even if it was reported for nivolumab and pembrolizumab that adding scoring of immune cell expression to tumor cells expression in PD-L1 assays did not improve the predictive value of PD-L1 test, data are sparse and future results from clinical trials may lead to include immune cells staining in PD-L1 scoring algorithm. However, when evaluating immune cells PD-L1 staining, we have found a poor concordance across the assays and LDT. Many factors may explain that harmonization of PD-L1 staining is more difficult to achieve for immune cells than for tumor cells. In particular, the usually low staining intensity in immune cells may be more sensitive to weak analytical differences between assays and significant inter and intraobserver variability can have more impact on the evaluation of concordance across PD-L1 assays and LDT.
Another important issue for PD-L1 testing is the interobserver reliability of the test. Our study was not designed to evaluate this parameter: all stained sections for each case were evaluated consecutively by a single pathologist trained on the 28-8 or 22C3 PD-L1 assays. Pathologist training is probably critically important for clinical practice since the generation of accurate PD-L1 test relies on the quality of staining and the accuracy of the pathological assessment. Several studies have reported that the interobserver concordance between pathologists is high for tumor cell staining assessment [12, 14, 17] . As reported in these studies, concordance between pathologists for immune cell scoring was very low, but data from studies with pathologists trained to a reference method (for instance the Ventana SP142 assay) are not yet available. Thus, the lack of standardized method use for immune cell scoring in our study as well as others limits the comparison of analytical performance between PD-L1 tests for immune cell staining.
Conclusion
In conclusion, our multicenter study has shown that PD-L1 testing in NSCLC can be harmonized across LDT with five different antibodies in various IHC platforms. These results will provide the basis for recommendations regarding PD-L1 testing and selected LDT will be further studied in larger cohorts in order to optimize and validate these protocols.
